CordenPharma International and GE Healthcare’s Dharmacon business have entered a strategic collaboration to create an end-to-end solution for oligonucleotide-based drug discovery. The collaboration will address the speed and capacity challenges researchers face when transitioning from research and preclinical stages to drug development and clinical trials. This changeover requires customers to move from a technology vendor to a contract manufacturing organization; compounding this step are ca...